Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral hexavalent rotavirus vaccine (Vero cell) Phase III in Chinese infants
CTR20180324Phase 3Completed
- Sponsor
- Wuhan Institute of Biological Products
- Start
- May 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of oral hexavalent reassortant live attenuated rotavirus vaccine in rotaviral diarrhea, sponsored by Wuhan Institute of Biological Products. Started May 2018; status: completed.
02
Drugs
oral hexavalent reassortant live attenuated rotavirus vaccine
03
Conditions
rotaviral diarrhea
Beyond the preview
Go deeper on CTR20180324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180324.